Palisade Bio

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Carlsbad, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for avoidance of acute and chronic post-surgical complications following gastrointestinal (GI) surgery, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LB1148 for the acceleration of time to return of bowel function following surgery.

Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery

E stablished academic and corporate executive with proven track record leading large, multinational organizations across the pharmaceutical and medical device industries

Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer

The Palisade Bio (PALI) board has announced a reverse stock split. These are the details.

Palisade Bio (PALI) Stock: Reverse Split Announced

Carlsbad, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Palisade Bio , Inc.  (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced a 1-for-50 reverse split of its common stock, par value $0.01 (“Common Stock”), effective at 4:01 PM ET today. Beginning on November 16, 2022, the Company's Common Stock will continue to trade on The Nasdaq Capital Market (“Nasdaq”) on a split adjusted basis under the trading symbol “PALI,” but will trade under the following new CUSIP number starting November 16, 2022: 696389204.

Palisade Bio Announces Reverse Stock Split

Carlsbad, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. , (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications (the “Company” or “Palisade”), reported its financial results for the quarter ended September 30, 2022. The Company also provided an update on the status of its clinical development programs for LB1148.

Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Board Appoints JD Finley to Interim Chief Executive Officer

Palisade Bio Announces Executive Leadership Transition

Carlsbad, CA, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Palisade Bio , Inc.  (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced its abstract was accepted for presentation at the American College of Surgeons (ACS) Clinical Congress 2022 being held October 16-20, 2022, in San Diego, CA.

Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022

Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it had made equity grants to two new employees under its 2021 Inducement Plan.

Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Live video webcast fireside chat on Thursday, September 29th at 11:30 AM ET Live video webcast fireside chat on Thursday, September 29th at 11:30 AM ET

Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference

CARLSBAD, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that following an internal strategic review, the Management Team and Board have implemented initiatives to streamline the organization, reduce operating expenses and preserve capital, with the goal of maximizing the advancement of its lead clinical program, LB1148.

Palisade Bio Streamlines Operations and Identifies Capital Efficiencies to Focus All Resources on Advancement of Lead Clinical Program, LB1148

Live moderated video webcast with members of Management to discuss pivotal Phase 3 study of lead asset in development, LB1148, on Friday, September 16th at 11:00 AM ET Live moderated video webcast with members of Management to discuss pivotal Phase 3 study of lead asset in development, LB1148, on Friday, September 16th at 11:00 AM ET

Palisade Bio to Present at the Virtual Investor Innovations in Intestinal Health - Launching a Pivotal Phase 3 Study for Return of Postoperative Bowel Function Event

Palisade Bio, Inc. (PALI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Palisade Bio, Inc. (PALI) Moves to Buy: Rationale Behind the Upgrade

Clarus Therapeutics Holdings

Timber Pharmaceuticals

T2 Biosystems

Penny stocks under $1 to watch this week. The post Top Penny Stocks To Buy?

Top Penny Stocks To Buy? 4 For Your Watch List Before Next Week

Avaya Holdings

Mind Medicine MindMed

Here's what you need to know about buying penny stocks on August 19th The post Hot Penny Stocks to Add to Your Watchlist Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Add to Your Watchlist Right Now

Vinco Ventures

Plus Therapeutics Inc

Here's what you need to know about buying penny stocks on August 18th The post Cheap Penny Stocks to Buy Now? 3 To Watch in August appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Cheap Penny Stocks to Buy Now? 3 To Watch in August

CARLSBAD, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the first patient has been dosed in its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery.

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

CARLSBAD, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $13.8 million, prior to deducting underwriting discounts and commissions and offering expenses, including full exercise of the underwriter's over-allotment option to purchase additional common stock shares and warrants.

Palisade Bio Announces Closing of $13.8 Million Upsized Underwritten Public Offering and Full Exercise of Over-Allotment Option

Quarter marked by initiation of Phase 3 study evaluating LB1148 for postoperative return of bowel function Quarter marked by initiation of Phase 3 study evaluating LB1148 for postoperative return of bowel function

Palisade Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

CARLSBAD, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the pricing of an underwritten public offering for gross proceeds of approximately $12 million prior to deducting underwriting discounts and commissions and offering expenses.

Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering

New website aligns with company's mission to become a global leader in addressing diseases linked to intestinal barrier disruption and establishing new standards of patient care in GI health New website aligns with company's mission to become a global leader in addressing diseases linked to intestinal barrier disruption and establishing new standards of patient care in GI health

Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health

CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the first patient has been screened in its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery.

Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Completion of enrollment for Phase 3 study targeted within 18-24 months

Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function

In-person presentation on Monday, June 13th at 1:45 PM PT In-person presentation on Monday, June 13th at 1:45 PM PT

Palisade Bio to Present at the 2022 BIO International Convention

Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022

Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it had made equity grants to four new employees under its 2021 Inducement Plan.

News for Palisade Bio Stock (PALI)